KIT in gastrointestinal stromal tumour

2 EU-approved indications in gastrointestinal stromal tumour need a KIT result: imatinib (advanced) and imatinib (adjuvant).

Disease setting

Approved indications, Gastrointestinal stromal tumour
DrugBiomarker requirementRegimenSettingConditions
KIT2
Imatinib
Glivec
Monotherapy
Adj.
After resection of Kit (CD117)-positive GIST; Significant risk of relapse; patients who have a low or very low risk of recurrence should not receive adjuvant treatment
Imatinib
Glivec
Monotherapy
Any line
advanced
None

3 approvals for GIST need no biomarker and apply whatever the result. All approvals for GIST

See also

Label wording2

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Imatinib (Glivec)
    the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
  2. Imatinib (Glivec)
    the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.